SDZ Share Price Performance
CHF 0
-45.11 (-100.00%)
Price CHF 0
Fair ValueCHF 81.99
Share Pricen/a
Narrative Update • Jul 10
Sandoz Group AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 56 Fair Values set on narratives written by author
SDZ Community Narratives
AN
Fair Value
·Fair Value CHF 81.99 20.5% undervalued intrinsic discount
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value CHF 70.74 7.9% undervalued intrinsic discount
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
1users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
Fair Value
·Fair Value CHF 54.19 20.3% overvalued intrinsic discount
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
Sandoz sells copycat medicines and biosimilars, but tougher rules, legal fights, and new trade barriers could make it harder to launch products and keep profits healthy. See why some think rising costs and pricing pressure may outweigh the upside from new biosimilar launches and manufacturing expansion.Read more
AN
CHF 54.19
20.3% overvalued intrinsic discount
Fair Value
Revenue
6.53% p.a.
Profit Margin
11.79%
Future PE
20.57x
Price in 2029
CHF 60.75
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
Sandoz leans into biosimilar medicines and faster in-house manufacturing to widen its reach beyond Europe and lift profits over time. The big question is whether fierce price competition, reliance on partners, and a slower-than-hoped push in the US could hold back those gains.Read more
AN
CHF 70.74
7.9% undervalued intrinsic discount
Fair Value
Revenue
6.25% p.a.
Profit Margin
14.2%
Future PE
22.4x
Price in 2029
CHF 79.31
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
Key Takeaways Rapid biosimilars adoption and manufacturing innovation are driving above-expected revenue growth, margin expansion, and sustainable profitability. Strong presence in emerging markets and expanding product pipeline enable diversified, resilient growth and long-term earnings acceleration.Read more
AN
CHF 81.99
20.5% undervalued intrinsic discount
Fair Value
Revenue
7.07% p.a.
Profit Margin
15.57%
Future PE
23.56x
Price in 2029
CHF 91.83
Trending Discussion
Recently Updated Narratives
AN
SDZ: Elevated Biosimilar Ambitions Will Face Fragile Earnings And Multiple Compression Risk
Fair Value: CHF 54.19 20.3% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDZ: Mixed Rating Shifts And Biosimilar Hub Investments Will Shape Future P/E
Fair Value: CHF 70.74 7.9% undervalued intrinsic discount
32 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Fair Value: CHF 81.99 20.5% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sandoz Group AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 05, 2026
- 2.11
- 47.50%
- 8.19%
- 56.6%
About SDZ
- Founded
- 1886
- Employees
- 22356
- CEO
- WebsiteView website
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Recent SDZ News & Updates
Narrative Update • Jun 26
